ECC 2015 | Molecular drivers of metastatic disease in breast cancer

Giuseppe Curigliano

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, from Istituto Europeo di Oncologia, Milan, Italy, explains that genetic differences between primary and metastatic breast cancer may have important clinical implications, including for the identification of biomarkers in disease progression.

Share this video  
Similar topics
Related videos
0:58
TNBC treatment: platinum-based therapy and PARP inhibition
Véronique Dieras
2:59
BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
Véronique Dieras
2:13
HER-2 conversion: a phenomenon in trastuzumab resistance
Russell Petty
1:45
Real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
Felice Musicco
4:18
IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC
David Spigel
Breast Cancer
ECC 2015
Interview
26th September 2015
More from Giuseppe Curigliano
Biomarker-driven therapies for triple-negative breast cancer
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals